iRhythm Technologies, Inc. (IRTC)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc.  (“iRhythm” or “the Company”) (NASDAQ: IRTC). Investors who purchased iRhythm securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether iRhythm has violated federal securities laws.

On May 30, 2023, iRhythm disclosed that “[o]n May 25, 2023, [the Company] received a warning letter from the U.S. Food and Drug Administration (the ‘FDA’), which resulted from the inspection of the Company’s facility located in Cypress, California that concluded in August 2022.  The warning letter alleges non-conformities to regulations for medical devices, including medical device reporting requirements, relating to the Company’s Zio AT System and medical device quality system requirements.”  On this news, iRhythm’s stock price fell $7.41 per share, or 6.09%, to close at $114.27 per share on May 31, 2023.

If you are aware of any facts relating to this investigation or purchased iRhythm shares, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.  The firm has recovered hundreds of millions of dollars for investors nationwide.  Attorney advertising. Prior results do not guarantee similar outcomes.